Sanofi

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Sanofi sits in the top decile of US sponsors by registered trial count (#47 of 15,742 sponsors by registered trial count).

713 total trials 69 currently recruiting 490 completed top decile by trial count

Sanofi: 713 sponsored US clinical trials, 69 recruiting.

Sanofi sponsors 713 registered US clinical trials on ClinicalTrials.gov, 69 of them currently recruiting, and 490 completed. 364 of these trials are in Phase 3-4 (later-stage) and 316 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dermatitis, Atopic, with 9 trials.

Top-decile sponsor footprint

Sanofi ranks in the top decile of sponsors by registered trial count (#47 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 45/100

490 of 597 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

713 total, page 15 of 15

COMPLETED Phase 3

Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine

NCT00662870

COMPLETED Phase 3

Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione

NCT00044447

COMPLETED Phase 3

Clinical Trial in Males With BPH (Enlarged Prostate)

NCT00029822

COMPLETED Phase 3

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

NCT00021255

COMPLETED Phase 4

Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy

NCT00358124

COMPLETED Phase 3

Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer

NCT00012389

COMPLETED Phase 3

Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00017459

COMPLETED Phase 2

Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer

NCT00819728

COMPLETED Phase 3

Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)

NCT00653341

COMPLETED Phase 1

Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

NCT01157156

COMPLETED Phase 3

Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer

NCT00273546

COMPLETED Phase 2

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT00401323

COMPLETED Phase 3

Docetaxel in Node Positive Adjuvant Breast Cancer

NCT00688740

← Previous Page 15 of 15

What is open in the Sanofi pipeline

69 recruiting of 713 indexed (10% open); 490 completed (69%).

Phase mix: 364 late (III/IV) vs 316 early (I/II) (balanced across stages).

Top condition: Dermatitis, Atopic (9 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Sanofi: open-pipeline peers nationwide

Peers matched on 713 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Sanofi sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 5%10%15%20%25% Total trials Recruiting share SanofiIcahn School of Medicine at Mount SinaiUniversity of MiamiWeill Medical College of Cornell UniversityThe University of Texas Health Science Center, HoustonChildren's Hospitals and Clinics of MinnesotaCytokineticsChildren's Oncology GroupUniversity of North Carolina, Chapel Hill
Sanofi sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sanofi sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 713 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this Sanofi page

713 registered trials is a research-attention snapshot, not an endorsement of Sanofi or any single study.

  • 69 of Sanofi's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Dermatitis, Atopic is the condition Sanofi studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dermatitis, Atopic trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sanofi pipeline card: 713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.